Sign Up Today and Learn More About Sparrow Pharmaceuticals Stock
Invest in or calculate the value of your shares in Sparrow Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Sparrow Pharmaceuticals Stock
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
About Sparrow Pharmaceuticals Stock
Founded
2013
Headquarters
Portland, OR, US
Industries
Software, Artificial Intelligence, Data and Analytics
Sparrow Pharmaceuticals Press Mentions
Stay in the know about the latest news on Sparrow Pharmaceuticals
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
biospace • Feb 02, 2026
Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes
globenewswire • Jan 06, 2026
New frontier for Seattle startups: Space, fusion, and battery companies buoy region’s VC activity
geekwire • Oct 20, 2025
Sanofi Pumps $625M Into Venture Arm to Back Breakthroughs in Early-Stage Startups
medcitynews • Oct 01, 2025
Sparrow Pharmaceuticals: $95 Million Series B Raised For Advancing Targeted Therapy For Type 2 Diabetes
pulse2 • Sep 27, 2025
Sparrow Pharmaceuticals Management
Leadership team at Sparrow Pharmaceuticals
President & CEO
Robert Jacks
Founder and CSO
David Katz
Join now and verify your accreditation status to gain access to:
- Sparrow Pharmaceuticals Current Valuation
- Sparrow Pharmaceuticals Stock Price
- Sparrow Pharmaceuticals Management
- Available deals in Sparrow Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Sparrow Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Sparrow Pharmaceuticals Revenue and Financials
- Sparrow Pharmaceuticals Highlights
- Sparrow Pharmaceuticals Business Model
- Sparrow Pharmaceuticals Risk Factors
- Sparrow Pharmaceuticals Research Report from SACRA Research
Trading Sparrow Pharmaceuticals Stock
How to invest in Sparrow Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Sparrow Pharmaceuticals through EquityZen funds. These investments are made available by existing Sparrow Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Sparrow Pharmaceuticals stock?
Shareholders can sell their Sparrow Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."